Logo image of BLND

BLEND LABS INC-A (BLND) Stock Fundamental Analysis

NYSE:BLND - New York Stock Exchange, Inc. - US09352U1088 - Common Stock - Currency: USD

3.26  -0.09 (-2.69%)

After market: 3.32 +0.06 (+1.84%)

Fundamental Rating

3

Taking everything into account, BLND scores 3 out of 10 in our fundamental rating. BLND was compared to 281 industry peers in the Software industry. The financial health of BLND is average, but there are quite some concerns on its profitability. BLND is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BLND has reported negative net income.
In the past year BLND has reported a negative cash flow from operations.
BLND had negative earnings in each of the past 5 years.
BLND had a negative operating cash flow in each of the past 5 years.
BLND Yearly Net Income VS EBIT VS OCF VS FCFBLND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

BLND has a worse Return On Assets (-33.98%) than 76.51% of its industry peers.
BLND has a worse Return On Equity (-70.90%) than 72.95% of its industry peers.
Industry RankSector Rank
ROA -33.98%
ROE -70.9%
ROIC N/A
ROA(3y)-100.5%
ROA(5y)-70.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLND Yearly ROA, ROE, ROICBLND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

BLND has a Gross Margin of 55.88%. This is in the lower half of the industry: BLND underperforms 62.63% of its industry peers.
BLND's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BLND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
BLND Yearly Profit, Operating, Gross MarginsBLND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

BLND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLND has more shares outstanding
Compared to 5 years ago, BLND has more shares outstanding
There is no outstanding debt for BLND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLND Yearly Shares OutstandingBLND Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
BLND Yearly Total Debt VS Total AssetsBLND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

BLND has an Altman-Z score of -4.49. This is a bad value and indicates that BLND is not financially healthy and even has some risk of bankruptcy.
BLND's Altman-Z score of -4.49 is on the low side compared to the rest of the industry. BLND is outperformed by 81.49% of its industry peers.
BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.49
ROIC/WACCN/A
WACC10.55%
BLND Yearly LT Debt VS Equity VS FCFBLND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BLND has a Current Ratio of 3.47. This indicates that BLND is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.47, BLND is in the better half of the industry, outperforming 76.87% of the companies in the same industry.
BLND has a Quick Ratio of 3.47. This indicates that BLND is financially healthy and has no problem in meeting its short term obligations.
BLND has a better Quick ratio (3.47) than 76.87% of its industry peers.
Industry RankSector Rank
Current Ratio 3.47
Quick Ratio 3.47
BLND Yearly Current Assets VS Current LiabilitesBLND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

BLND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.95%, which is quite impressive.
BLND shows a small growth in Revenue. In the last year, the Revenue has grown by 3.29%.
Measured over the past years, BLND shows a very strong growth in Revenue. The Revenue has been growing by 26.16% on average per year.
EPS 1Y (TTM)80.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)3.29%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%14.69%

3.2 Future

Based on estimates for the next years, BLND will show a very strong growth in Earnings Per Share. The EPS will grow by 66.17% on average per year.
BLND is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.48% yearly.
EPS Next Y159.5%
EPS Next 2Y84.46%
EPS Next 3Y66.17%
EPS Next 5YN/A
Revenue Next Year12.83%
Revenue Next 2Y17.3%
Revenue Next 3Y19.48%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BLND Yearly Revenue VS EstimatesBLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
BLND Yearly EPS VS EstimatesBLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

BLND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 68.48 indicates a quite expensive valuation of BLND.
BLND's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 20.77. BLND is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 68.48
BLND Price Earnings VS Forward Price EarningsBLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLND Per share dataBLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BLND's earnings are expected to grow with 66.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y84.46%
EPS Next 3Y66.17%

More info and screens

0

5. Dividend

5.1 Amount

BLND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLEND LABS INC-A

NYSE:BLND (5/1/2025, 8:47:30 PM)

After market: 3.32 +0.06 (+1.84%)

3.26

-0.09 (-2.69%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners73.95%
Inst Owner Change0.01%
Ins Owners3.57%
Ins Owner Change2.54%
Market Cap846.49M
Analysts80
Price Target5.24 (60.74%)
Short Float %3.87%
Short Ratio2.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0%
Min EPS beat(2)-100%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)18.8%
Min EPS beat(4)-100%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)15.93%
EPS beat(12)8
Avg EPS beat(12)7.94%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.9%
Min Revenue beat(2)-1.91%
Max Revenue beat(2)5.71%
Revenue beat(4)2
Avg Revenue beat(4)1.18%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)5.71%
Revenue beat(8)4
Avg Revenue beat(8)1.93%
Revenue beat(12)7
Avg Revenue beat(12)2.88%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.19%
PT rev (3m)-5.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-10.25%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-15.16%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-6.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 68.48
P/S 5.22
P/FCF N/A
P/OCF N/A
P/B 9.92
P/tB 10.17
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)0.05
Fwd EY1.46%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.62
BVpS0.33
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.98%
ROE -70.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.88%
FCFM N/A
ROA(3y)-100.5%
ROA(5y)-70.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
F-Score5
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 430.06%
Cap/Sales 6.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.47
Quick Ratio 3.47
Altman-Z -4.49
F-Score5
WACC10.55%
ROIC/WACCN/A
Cap/Depr(3y)157.7%
Cap/Depr(5y)104.5%
Cap/Sales(3y)2.44%
Cap/Sales(5y)1.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y159.5%
EPS Next 2Y84.46%
EPS Next 3Y66.17%
EPS Next 5YN/A
Revenue 1Y (TTM)3.29%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%14.69%
Revenue Next Year12.83%
Revenue Next 2Y17.3%
Revenue Next 3Y19.48%
Revenue Next 5YN/A
EBIT growth 1Y67.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year230.9%
EBIT Next 3Y82.22%
EBIT Next 5YN/A
FCF growth 1Y82.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.78%
OCF growth 3YN/A
OCF growth 5YN/A